Pay in 4 interest-free payments of $6.79 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Activity of targeted molecular therapeutics against primary AML cells: putative role of the bone marrow microenvironment
Specific Populations No clinically significant differences in the pharmacokinetics of selinexor were observed based on age (18 to 94 years old), sex, body weight (36 to 168 kg), ethnicity, mild to severe renal impairment (CLCR: 15 to 89 mL/min, estimated by the Cockcroft-Gault equation), and disease type (hematological, solid tumor)
The survival rate of cells treated with crocin is comparable to that of cells treated with amifostinethe only radioprotector clinically approved by the US Food and Drug Administration (FDA) after irradiation with a dose of 6 Gy
precursors of glutathione + MSM precursors of glutathione + MSM benefits
US$ 20.81
US$ 20.12
US$ 28.27
US$ 29.64
